A study published in Stem Cell Translational Medicine (SCTM) showed that stem cells can be both safe and effective in the treatment of peripheral arterial disease (PAD). AICLI (Angitis induced critical limb ischemia) treated using stem cells on a long-term showed both safe and effective prognosis. The study published that stem cells can definitely be an option for those who suffer from serious peripheral arterial diseases.
The condition AICLI is an inflammation of the blood vessels that can lead to serious blockage of the arteries of the upper and lower extremities. It is accompanied by pain, impaired mobility, amputation of the limb and thereby result in death.The classical treatments such as endovascular surgical intervention are unfeasible in nearly 15-20% of the cases. Thus in these patients stem cell therapy is absolutely promising. A purified CD34+ cell transplant is a favourable alternative for this condition.
During the study, 27 patients with AICLI were tracked by researchers for a period of 5 years. Each of the patients had received stem cell intramuscular injections to treat this condition. The parameters evaluated for the period of 5 years were:
Reduction of pain
Amputation free survival
The Head researcher Zhihui Dong and his colleague Weiguo from the Department of vascular surgery conducted the complete study. The results showed that the major amputation free survival of these patients accrued to a total of 88.89% and the level of pain also plummeted in these patients more than half.
In 65% of the cases, limbs were salvaged and they fully recovered. Most of them returned back to their original jobs by 260 weeks. Thus, long-term treatment using stem cells were efficient and durable not in just recovery but also in improving the quality of life of the individual.Thus, the study proved that long-term results in 27 patients with debilitating disease using stem cells proved to be highly effective in patients with no treatment options.